23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Pfizer bets big on next-generation CAR-T

Pfizer is entering the in vivo CAR-T race by licensing three preclinical candidates from Chinese biotech company Starna Therapeutics.
Advertisement

The US pharmaceutical giant will pay USD 330 million upfront, with the potential for a further USD 2.3 billion in milestone payments, for the rights to develop and commercialise three in vivo CAR-T programmes outside Greater China.

The programmes, which target autoimmune diseases, are currently in “pre-IND” development.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.031|